Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor.

Dottorini L, Catena L, Sarno I, Di Menna G, Marte A, Novelli E, Rusca C, Bajetta E.

J Geriatr Oncol. 2019 Mar;10(2):356-358. doi: 10.1016/j.jgo.2018.10.007. Epub 2018 Oct 14.

PMID:
30333087
2.

Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement.

Dottorini L, Catena L, Sarno I, Di Menna G, Marte A, Bajetta E.

Oncology. 2018;94 Suppl 1:6-9. doi: 10.1159/000489062. Epub 2018 Jul 23.

3.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F.

Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

PMID:
29655834
4.

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPscore Working Group.

Endocr Relat Cancer. 2018 Jun;25(6):607-618. doi: 10.1530/ERC-17-0489. Epub 2018 Mar 20.

5.

Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.

Bajetta E, Catena L, Pusceddu S, Spada F, Iannacone C, Sarno I, Di Menna G, Dottorini L, Marte AM.

Neuroendocrinology. 2018;106(4):307-311. doi: 10.1159/000479587. Epub 2017 Jul 26.

PMID:
28743120
6.

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.

Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V.

Clin Colorectal Cancer. 2017 Sep;16(3):e191-e198. doi: 10.1016/j.clcc.2016.09.007. Epub 2016 Oct 6.

PMID:
27979717
7.

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer.

Di Bartolomeo M, Pietrantonio F, Rulli E, Poli D, Berenato R, Caporale M, Bajetta E, Floriani I.

Tumori. 2016 Aug 3;102(4):e15-9. doi: 10.5301/tj.5000480.

PMID:
27032700
8.

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME.

Endocr Relat Cancer. 2015 Dec;22(6):933-40. doi: 10.1530/ERC-15-0314. Epub 2015 Sep 15.

9.

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I, Miceli R.

Gastric Cancer. 2016 Apr;19(2):412-420. doi: 10.1007/s10120-015-0495-y. Epub 2015 Apr 11.

PMID:
25862567
10.

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.

Di Bartolomeo M, Ciarlo A, Bertolini A, Barni S, Verusio C, Aitini E, Pietrantonio F, Iacovelli R, Dotti KF, Maggi C, Perrone F, Bajetta E.

Eur J Cancer. 2015 Mar;51(4):473-81. doi: 10.1016/j.ejca.2014.12.020. Epub 2015 Jan 27.

PMID:
25637137
11.

Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.

Bajetta E, Catena L, Biondani P, Pusceddu S, Valente M, Bianco N, Novelli E.

Anticancer Res. 2014 Oct;34(10):5657-60.

PMID:
25275070
12.

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens.

Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F.

Cancers (Basel). 2014 Aug 29;6(3):1753-68. doi: 10.3390/cancers6031753.

13.

Safety profile and treatment response of everolimus in different solid tumors: an observational study.

Verzoni E, Pusceddu S, Buzzoni R, Garanzini E, Damato A, Biondani P, Testa I, Grassi P, Bajetta E, de Braud F, Procopio G.

Future Oncol. 2014;10(9):1611-7. doi: 10.2217/fon.14.31. Erratum in: Future Oncol. 2014 Aug;10(10):1810. DeBraud, Filippo [corrected to de Braud, Filippo].

PMID:
25145431
14.

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.

Buzzoni R, Pusceddu S, Bajetta E, De Braud F, Platania M, Iannacone C, Cantore M, Mambrini A, Bertolini A, Alabiso O, Ciarlo A, Turco C, Mazzaferro V.

Ann Oncol. 2014 Aug;25(8):1597-603. doi: 10.1093/annonc/mdu175. Epub 2014 May 14.

PMID:
24827133
15.

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.

Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F.

Cancer. 2014 Aug 15;120(16):2457-63. doi: 10.1002/cncr.28726. Epub 2014 Apr 18.

16.

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.

Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.

Ann Oncol. 2014 Jul;25(7):1373-8. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12.

PMID:
24728035
17.

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M.

J Exp Clin Cancer Res. 2013 Oct 25;32:82. doi: 10.1186/1756-9966-32-82.

18.

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E; Italian Trials in Medical Oncology (ITMO) group.

Ann Oncol. 2013 Dec;24(12):2967-71. doi: 10.1093/annonc/mdt375. Epub 2013 Sep 24.

19.

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; Italian Trials in Medical Oncology Group.

Target Oncol. 2014 Jun;9(2):155-62. doi: 10.1007/s11523-013-0283-8. Epub 2013 Jul 3.

PMID:
23821376
20.

Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.

Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS.

Clin Cancer Res. 2013 Jul 15;19(14):3987-95. doi: 10.1158/1078-0432.CCR-13-0027. Epub 2013 Jun 6.

21.

Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.

Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, Grassi P, Di Bartolomeo M.

Am J Clin Oncol. 2014 Dec;37(6):545-9. doi: 10.1097/COC.0b013e31827ecd1d.

PMID:
23428953
22.

Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.

Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T; RADIANT-2 Study Group.

Oncologist. 2013;18(1):46-53. doi: 10.1634/theoncologist.2012-0263. Epub 2012 Dec 21.

23.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM.

Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16.

PMID:
23168362
24.

The cost of unresectable stage III or stage IV melanoma in Italy.

Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, Guida M, Romanini A, Chiarion-Sileni V, Pigozzo J, Di Giacomo AM, Calandriello M, Didoni G, van Baardewijk M, Konto C, Lucioni C.

J Exp Clin Cancer Res. 2012 Nov 1;31:91. doi: 10.1186/1756-9966-31-91.

25.

New perspectives in the treatment of neuroendocrine tumours.

Bajetta E, Catena L, Valente M, Bianco N, Bellomo F, Bombardieri E.

Anticancer Res. 2012 Oct;32(10):4193-200. Review.

PMID:
23060539
26.
27.

Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?

Catena L, Bichisao E, Milione M, Valente M, Platania M, Pusceddu S, Ducceschi M, Zilembo N, Formisano B, Bajetta E.

Tumori. 2011 Sep-Oct;97(5):564-7. doi: 10.1700/989.10712.

PMID:
22158484
28.

Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.

Celio L, Denaro A, Agustoni F, Bajetta E.

J Support Oncol. 2012 Mar-Apr;10(2):65-71. doi: 10.1016/j.suponc.2011.06.007. Epub 2011 Sep 23.

PMID:
22005217
29.

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, Szczesna A, Reiterer P, Saleh M, Arrieta O, Bajetta E, Webb RT, Raats J, Benner RJ, Fowst C, Meech SJ, Readett D, Schiller JH.

J Clin Oncol. 2011 Jul 1;29(19):2667-74. doi: 10.1200/JCO.2010.32.8971. Epub 2011 May 31.

PMID:
21632509
30.

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.

Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E.

BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23.

31.

A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer.

Pusceddu S, Bajetta E, Carcangiu ML, Formisano B, Ducceschi M, Buzzoni R.

Crit Rev Oncol Hematol. 2012 Feb;81(2):185-95. doi: 10.1016/j.critrevonc.2011.03.008. Epub 2011 Apr 23. Review.

PMID:
21515070
32.

Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges.

Catena L, Bajetta E, Milione M, Ducceschi M, Valente M, Dominoni F, Colonna V.

Target Oncol. 2011 Jun;6(2):65-8. doi: 10.1007/s11523-011-0171-z. Epub 2011 Apr 6.

PMID:
21468754
33.

Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.

Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E.

J Clin Oncol. 2011 May 20;29(15):2004-10. doi: 10.1200/JCO.2010.29.5436. Epub 2011 Apr 4.

PMID:
21464401
34.

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E.

Br J Cancer. 2011 Apr 12;104(8):1256-61. doi: 10.1038/bjc.2011.103. Epub 2011 Mar 29.

35.

An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.

Zilembo N, Vitali M, Pietrantonio F, Platania M, Del Vecchio M, Bajetta E.

Tumori. 2010 Nov-Dec;96(6):1031-4. Review.

PMID:
21388071
36.

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.

Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B.

Ann Oncol. 2011 Aug;22(8):1812-23. doi: 10.1093/annonc/mdq651. Epub 2011 Feb 15.

PMID:
21324953
37.

Pharmacological therapy of neuroendocrine tumors.

Rinke A, Ricci S, Bajetta E, Jelic S.

Tumori. 2010 Sep-Oct;96(5):847-57. No abstract available.

PMID:
21302642
38.

Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?

Procopio G, Verzoni E, Guadalupi V, Iacovelli R, Bajetta E.

Tumori. 2010 Sep-Oct;96(5):794-5. No abstract available.

PMID:
21302633
39.

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer.

Di Bartolomeo M, Pietrantonio F, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E.

Drugs Aging. 2011 Feb 1;28(2):83-91. doi: 10.2165/11584710-000000000-00000. Review.

PMID:
21155618
40.

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).

Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; ISA Co-Authors, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E.

Lung Cancer. 2011 Jul;73(1):78-88. doi: 10.1016/j.lungcan.2010.10.020. Epub 2010 Dec 8.

PMID:
21144614
41.

Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.

Procopio G, Guadalupi V, Giganti MO, Mariani L, Salvioni R, Nicolai N, Capone F, Valdagni R, Bajetta E.

BJU Int. 2011 Jul;108(2):223-7. doi: 10.1111/j.1464-410X.2010.09825.x. Epub 2010 Nov 15.

42.

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A.

Clin Cancer Res. 2010 Dec 1;16(23):5862-72. doi: 10.1158/1078-0432.CCR-10-2363. Epub 2010 Oct 28. Erratum in: Clin Cancer Res. 2011 Feb 1;17(3):630.

43.

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.

Bracarda S, Bellmunt J, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B.

BJU Int. 2011 Jan;107(2):214-9. doi: 10.1111/j.1464-410X.2010.09707.x. Epub 2010 Oct 13.

44.

Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report.

Valente M, Catena L, Milione M, Pusceddu S, Formisano B, Bajetta E.

Case Rep Oncol. 2010 Jul 2;3(2):202-207.

45.

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.

Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E; Italian Trials in Medical Oncology Group.

Support Care Cancer. 2011 Aug;19(8):1217-25. doi: 10.1007/s00520-010-0941-7. Epub 2010 Jun 25.

46.

Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report.

Pietrantonio F, Di Bartolomeo M, Buzzoni R, Bajetta E.

Tumori. 2010 Jan-Feb;96(1):154-6.

PMID:
20437874
47.

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.

Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C.

J Clin Oncol. 2010 May 20;28(15):2604-11. doi: 10.1200/JCO.2009.27.3649. Epub 2010 Apr 20.

PMID:
20406925
48.

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V.

J Clin Oncol. 2010 May 1;28(13):2144-50. doi: 10.1200/JCO.2009.26.7849. Epub 2010 Apr 5.

PMID:
20368553
49.

Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis.

Pusceddu S, Catena L, Valente M, Buzzoni R, Formisano B, Del Vecchio M, Ducceschi M, Tavecchio L, Fabbri A, Bajetta E.

J Thorac Dis. 2010 Mar;2(1):16-20.

50.

Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.

Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, Bombardieri E.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):84-91.

Supplemental Content

Loading ...
Support Center